Xilio Development Inc (XLO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Xilio Development Inc (XLO) has a cash flow conversion efficiency ratio of -0.260x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.76 Million) by net assets ($72.26 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see XLO stock market capitalisation for the company's overall valuation and market capitalisation.
Xilio Development Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Xilio Development Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Xilio Development Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xilio Development Inc ranked by their cash flow conversion efficiency. Explore cash flow quality index of Xilio Development Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SensorView Co Ltd
KQ:321370
|
-0.080x |
|
AML3D Ltd
AU:AL3
|
-0.076x |
|
Hindustan Composites Limited
NSE:HINDCOMPOS
|
0.018x |
|
Nahar Poly Films Limited
NSE:NAHARPOLY
|
0.071x |
|
OnMobile Global Limited
NSE:ONMOBILE
|
0.086x |
|
Top Systems-L
TA:TOPS
|
0.143x |
|
Dutaland Bhd
KLSE:3948
|
-0.019x |
|
JLS Co.Ltd
KQ:040420
|
0.043x |
Annual Cash Flow Conversion Efficiency for Xilio Development Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Xilio Development Inc from 2019 to 2025. View Xilio Development Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $35.27 Million | $-4.99 Million | -0.142x | +86.45% |
| 2024-12-31 | $17.60 Million | $-18.38 Million | -1.044x | +43.95% |
| 2023-12-31 | $36.83 Million | $-68.62 Million | -1.863x | -159.96% |
| 2022-12-31 | $105.65 Million | $-75.72 Million | -0.717x | -64.59% |
| 2021-12-31 | $185.43 Million | $-80.75 Million | -0.435x | -106.38% |
| 2020-12-31 | $-5.29 Million | $-36.09 Million | 6.829x | +1573.87% |
| 2019-12-31 | $38.51 Million | $-17.84 Million | -0.463x | -- |
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumo… Read more